Gene therapy trial for RPGR-related vision loss
Part of Eyes & vision clinical trials.
This early study tests a gene therapy designed for people whose vision problems are caused by an RPGR genetic change. It may help slow or improve the eye disease by treating the underlying cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able and willing to follow all study visit and testing instructions
- Be a male age 8 to 45 when you sign consent
- Have a confirmed genetic change (variant) in the RPGR gene
- Do not have other inherited retinal genetic causes of vision loss
- Have not had any prior gene therapy to the eye (or any prior gene therapy product)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
This trial tests a gene therapy for people with a specific genetic form of retinitis pigmentosa (caused by changes in the RPGR gene). It aims to improve vision and slow disease progression.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
Hear when a new X-Linked Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.